Bone Strength/Bone Mass Discrepancy in Glucocorticoid-Treated Adult Mice.
Bone Strength/Bone Mass Discrepancy in Glucocorticoid-Treated Adult Mice.
复制标题
糖皮质激素治疗的成年小鼠的骨强度/骨量差异
作者：
Dubrovsky AM;Nyman JS;Uppuganti S;Chmiel KJ;Kimmel DB;Lane NE
糖皮质激素以一种骨量测量低估的方式增加患者的骨脆性。这项研究的目的是确定成年小鼠是否能够模拟这种骨强度/骨量差异。将4 2只13周龄BALB/CJ小鼠随机分为赋形剂组和糖皮质激素组，分别植入赋形剂和6-甲基强的松龙微丸，分别于6 0和12 0 后剖检。在右侧股骨中央(皮质骨丰富)和第六腰椎体(LVB6；松质骨丰富)评估骨强度和骨量/微结构。用质子-核磁共振(1H-核磁共振)弛豫计量法分析整个右侧股骨的结合水。数据采用双因素方差分析，以时间(60天和120天)和治疗(载体和糖皮质激素)为主要影响因素。有意义的交互作用被进一步用Tukey的后随机测试进行了分析。在糖皮质激素组，无论治疗时间长短，CF中的大多数骨强度测量都较低，没有时间×治疗的交互作用。然而，CF中的骨量测量显示出显著的时间×治疗交互作用(p=0.0001)。LVB6中的骨强度测量显示出时间×治疗交互作用(p <； 0.02)，使得糖皮质激素治疗120 天后LVEB6强度低于赋形剂治疗120 天。糖皮质激素治疗组(p=0.0001)和治疗时间组(p <； 0.02)的全股骨体重均较低，且存在显著的时间×治疗交互作用(p=0.005)。雄性BALB/CJ小鼠接受糖皮质激素治疗后，皮质骨和松质骨的骨强度均下降，其出现时间或早于或大于治疗相关的骨量/微结构改变。成年小鼠可能是研究糖皮质激素治疗患者骨强度/骨量差异的一个很好的模型。©2020作者。JBMR Plus由威利期刊有限责任公司出版。代表美国骨骼和矿物研究学会。
Glucocorticoids increase bone fragility in patients in a manner that is underestimated by bone mass measurement. This study aimed to determine if the adult mouse could model this bone strength/bone mass discrepancy. Forty‐two 13‐week‐old BALB/cJ mice were randomized into vehicle and glucocorticoid groups, implanted with vehicle or 6‐methylprednisolone pellets, and necropsied after 60 and 120 days. Bone strength and bone mass/microarchitecture were assessed at the right central femur (CF; cortical‐bone–rich) and sixth lumbar vertebral body (LVB6; trabecular‐bone–rich). Bound water (BW) of the whole right femur was analyzed by proton‐nuclear magnetic resonance (1H‐NMR) relaxometry. Data were analyzed by two‐factor ANOVA with time (day 60 and day 120) and treatment (vehicle and glucocorticoid) as main effects for all data. Significant interactions were further analyzed with a Tukey's post hoc test. Most bone strength measures in the CF were lower in the glucocorticoid group, regardless of the duration of treatment, with no time × treatment interaction. However, bone mass measures in the CF showed a significant time × treatment interaction (p = 0.0001). Bone strength measures in LVB6 showed a time × treatment interaction (p < 0.02) such that LVB6 strength was lower after 120 days of glucocorticoids compared with 120 days of vehicle treatment. Whole‐femur–BW was lower with both glucocorticoid treatment (p = 0.0001) and time (p < 0.02), with a significant time × treatment interaction (p = 0.005). Glucocorticoid treatment of male BALB/cJ mice resulted in the lowering of bone strength in both cortical and trabecular bone that either appeared earlier or was greater than the treatment‐related changes in bone mass/microarchitecture. The adult mouse may be a good model for investigating the bone strength/mass discrepancy observed in glucocorticoid‐treated patients. © 2020 The Authors. JBMR Plus published by Wiley Periodicals LLC. on behalf of American Society for Bone and Mineral Research.